- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02786043
PK Study to Evaluate the Effect of PLC on Healthy Chinese Subjects by Multiple-doses
May 25, 2016 updated by: Lee's Pharmaceutical Limited
An Open-label, Single Arm, Self-controlled Safety and Pharmacokinetics Study to Evaluate the Effect of Propionyl L-carnitine Hydrochloride on Healthy Chinese Subjects by Diet and Multiple-doses
The main objective is to evaluate the effect of Propionyl-L-Carnitine Hydrochloride on clinical pharmacokinetic characteristics and its effect of clinical pharmacokinetic characteristics and safety on healthy Chinese subjects to provide a basis for market authorization registration
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a single group subject, open-label, self-controlled, 3 periods, multi-doses administration trial.
12 Healthy Chinese volunteers satisfying inclusion criteria were enrolled with equal number of male and female.
Each subject goes through a 7-day Run-in period to eliminate the remaining L-carnitine like substance in the food to ensure the baseline level of endougenous L-Carnitien is stable;In period III, during the first 4 days,all healthy subjects take oral Propionyl-L-Carnitine 1g twice daily; on day 5, all healthy subjects take oral Propionyl-L-Carnitine 1g during fasting.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sex: Male and female of same proportion. Healthy individuals.
- Age: 19 to 45. Similar age.
- Weight: All subjects need to weigh ≥50 kg. BMI within 19~24 kg/m2. Similar weight between subjects.;
- Blood pressure: SBP 90-139mmHg,DBP 60-89 mmHg;
- Subjects need to understand and agree before the start of trial and signed the informed consent form.
- Subjects have to be able to communicate with the investigator and comply with the trial protocol.
Exclusion Criteria:
Laboratory investigations:
- Any items of safety evaluation index baseline values considered to be clinically significant abnormal by the investigator before the study;
- Hepatitis B surface antigen positive;
- Hepatitis C antibody positive;
- HIV, Syphilis positive;
- During screening or 1st day of trial before drug administration, any ECG abnormality shown
Drug history:
- Taken any drugs that inhibit or induce hepatic metabolism of drug 1 month prior to the trial;
- Taken any drugs within 2 weeks prior to the trial (including prescription drugs, non-prescription drugs and Chinese herbal drugs);
Past medical history and surgical history:
- Past medical history includes structural heart diseases, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmias, Torsade de pointes, ventricular tachycardia, Long QT syndrome or signs and symptoms of Long QT syndrome with family history (evidenced by genetic testing or relatives died of sudden cardiac death at a young age);
- Thyroid disease history or received thyroid surgery;
- Immune diseases history (e.g. thymus disorder history);
- Received surgery within 6 months prior to the trial;
- Serious gastrointestinal disease history (e.g. clinically significant gallbladder disease, known or suspected jaundice, hepatocellular adenoma, hepatic cavernous hemangioma or other hepatic disease);
- Any gastrointestinal, hepatic or renal diseases that affect drug absorption or metabolism within 6 months prior to the trial (excluded regardless resolved);
- Any serious cerebrovascular, respiratory, metabolic and neurological disease history;
- Hematological disease like clotting disorder;
- Tumor history;
- Hypokalemia, hypocalcemia according to the lower limit of reference range provided by the clinical laboratory;
Lifestyle:
- Frequent alcohol intake within 6 months prior to the trial. Over 14 units of alcohol intake per week (1 unit = 17.7ml ethanol, 1 unit = 357 ml 5% alcohol beer or 44ml 40% liquor or 147 ml 12% alcohol wine);
- Smoke >1 cigarette per day within 3 months prior to the trial;
- Drug abuse history and taken drugs (marijuana, cocaine, opiates, benzodiazepines, amphetamines, barbiturates, methadone, tricyclic antidepressants, etc.) within 1 year prior to the trial;
- Drink excess tea, coffee or caffeine-containing drinks (more than 8 cups) per day 2 days before drug administration to 8 days after drug administration;
- Drink grapefruit juice 2 days before drug administration to 8 days after drug administration;
Others:
- Did not consent to use effective contraceptive methods from enrollment to 3 months after drug administration;
- Hypersensitivity including known allergy to the excipients of the drug (microcrystalline cellulose, lactose, silica powder, sodium carboxymethyl starch, magnesium stearate);
- Participated in any other clinical trials within 3 months prior to the trial or planned to participate in any other clinical trials 1 month after enrollment to the last drug administration visit;
- Blood donation within 3 months prior to the trial or planned to donate blood 1 month after enrollment to the last drug administration visit;
- Any food allergy or special request to diet and cannot comply to unified diet;
- Subjects considered to be excluded by investigator;
For female subjects, any following criteria met, apart from criteria above, should also be excluded:
- Taken oral contraceptive pills within 1 month prior to the trial;
- Long term use of estrogen or progesterone injection or implants within 6 months prior to the trial;
- Fertile female subjects without using contraceptive method 2 weeks prior to the trial;
- Fertile female subjects and spouse not consent to use following contraceptive method, condoms, intra-uterine device, etc. after enrollment to 3 months after drug administration;
- During pregnancy or lactation;
- Urine pregnancy test positive;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
|
1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under Curve (AUC)
Time Frame: Day 3 and 4, 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24h after drug administration on day 5
|
To observe area under curve characteristics of Propionyl-L-Carnitine in single or multiple dose groups
|
Day 3 and 4, 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24h after drug administration on day 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cumulative urine excretion rate
Time Frame: 0h-2h, 2-4h, 4-8h, 8-12h, 12-24h after drug administration
|
To compare the cumulative urine excretion rate in multiple dose with that in single dose
|
0h-2h, 2-4h, 4-8h, 8-12h, 12-24h after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Heng-yan Qu, National Clinical Trial Institution of Affiliated Hospital of Military Medical Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
January 1, 2016
Study Registration Dates
First Submitted
May 24, 2016
First Submitted That Met QC Criteria
May 25, 2016
First Posted (Estimate)
May 30, 2016
Study Record Updates
Last Update Posted (Estimate)
May 30, 2016
Last Update Submitted That Met QC Criteria
May 25, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Zhaoke-201506-PLC-multidose
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Diseases
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
TakedaCompletedPeripheral Arterial DiseasesGeorgia, Kazakhstan, Russian Federation
-
Medtronic EndovascularCompletedPeripheral Arterial DiseasesGermany
-
VA Eastern Colorado Health Care SystemCompletedPeripheral Arterial DiseasesUnited States
-
National Cheng-Kung University HospitalDepartment of Health, Executive Yuan, R.O.C. (Taiwan)CompletedPeripheral Arterial DiseasesTaiwan
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Propionyl-L-Carnitine Hydrochloride
-
Lee's Pharmaceutical LimitedCompletedPeripheral Arterial Disease
-
Sigma-Tau Research, Inc.Colorado Prevention CenterCompletedPeripheral Vascular Diseases | Intermittent ClaudicationUnited States
-
sigma-tau i.f.r. S.p.A.TerminatedUlcerative ColitisNetherlands, Romania, Israel, Czech Republic, Italy, Belgium, Russian Federation, Slovakia
-
sigma-tau i.f.r. S.p.A.PRA Health SciencesTerminatedUlcerative ColitisPoland, Hungary, Austria, France, Germany, Latvia, Lithuania, Spain
-
Lee's Pharmaceutical LimitedNanjing Medical UniversityCompletedPeripheral Arterial DiseaseChina
-
sigma-tau i.f.r. S.p.A.CompletedUlcerative ColitisItaly, Lithuania, Poland, Russian Federation
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Ain Shams UniversityCompleted
-
Vanderbilt University Medical CenterCompletedLung Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Primary Pulmonary Hypertension | Carnitine Nutritional DeficiencyUnited States